By selecting the Yes option, leaving Amgen.sa option you understand that you are leaving the corporate page of Amgen Saudi Arabia and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Saudi Arabia is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Saudi Arabia. If You reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
We recognize that this may be a challenging and stressful time, especially if you are a patient managing a serious illness. As the COVID-19 pandemic continues to evolve, we are committed to doing everything we can to deliver for patients, to keep our staff and their families safe, and to help the communities where we live and work reduce the number of people exposed to the virus. Medical professionals around the world are working tirelessly on the front lines to achieve this and we would like to express our deep gratitude to them. We will continue to keep you informed and are committed to continuing to deliver to you our medicines.
For general information in Europe related to the pandemic, please see COVID-19 guidance from the World Health Organization or the European Center for Disease Control and Education
For further information on how Amgen is responding to the pandemic, please visit Amgen’s COVID-19 Information Center. Local contact information by country can be found here (Amgen’s global website).
Patients with cancer are disproportionately affected by COVID-19 and this has affected presentation, referral, diagnosis and treatment. Delays across each of these stages are predicted to increase the number of deaths from cancer that could otherwise be avoided. The video below (using UK data) presents this evidence and makes an urgent ‘call to action’ on behalf of patients, for us to work together to increase capacity in cancer care.